A clinical trial assessing MET-097i in people with obesity, overweight, and Type 2 diabetes
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs MET 097 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2025 New trial record
- 07 Jan 2025 According to Metsera media release, company plans to launch an additional study across multiple monthly doses in early 2025.